Significant longer PFS among patients who received zanubrutinib vs ibrutinib
In this MEDtalk, Jennifer Brown from the Dana Faber Cancer Institute in Boston, USA, presents the results from the ALPINE study – a multinational, phase 3, head-to-head trial for patients with r/r CLL treated with ibrutinib vs zanubrutinib. Zanubrutinib is a second generation Bruton’s tyrosine kinase (BTK) inhibitor for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Compared with ibrutinib, patients treated with zanubrutinib have a significant longer PFS. At the same time, zanubrutinib was associated with fewer cardiac adverse events.